Literature DB >> 8627655

Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS.

F Baldanti1, M R Underwood, S C Stanat, K K Biron, S Chou, A Sarasini, E Silini, G Gerna.   

Abstract

Three human cytomegalovirus (HCMV) strains (VR4760, VR4955, and VR5120) showing double resistance to ganciclovir (GCV) and foscarnet (PFA) were isolated from three patients with AIDS who underwent multiple sequential courses of therapy with GCV and PFA (A. Sarasini, F. Baldanti, M. Furione, E. Percivalle, R. Brerra, M. Barbi, and G. Gerna, J. Med. Virol., 47:237-244, 1995). We previously demonstrated that the three strains were genetically unrelated and that each of them was present as a single viral population in vivo. Thus, in each of the three cases, a single viral strain was resistant to both GCV and PFA. In the present paper, we report the characterization of the molecular bases of the double resistance and demonstrate that the PFA resistance is associated with a slower replication of HCMV strains in cell cultures. Sequencing of the UL97 and UL54 genes, GCV anabolism assays, and marker transfer experiments showed that GCV resistance was due to single amino acid changes in the UL97 gene product (VR4760, Met-460 --> Ile; VR4955, Ala-594 --> Val; VR5120, Leu595 --> Ser), while single amino acid changes in domain II of the DNA polymerase (VR4760 and VR5120, Val-715 --> Met; VR4955, Thr-700 --> Ala) were responsible for both the PFA resistance and the slow-growth phenotype. Thus, in these three cases, double resistance to GCV and PFA was not due to a single mutation conferring cross-resistance or to the presence of a mixture of strains with different drug susceptibilities. The HCMV DNA polymerase recombinant strains carrying the mutations conferring PFA resistance were sensitive to GCV and (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). In addition, the same UL54 mutations were responsible for the slow growth of the clinical isolates, since the recombinant strains showed a marked delay in immediate-early antigen plaque formation and a reduction of infectious virus yield compared with AD169, from which they were derived. These results may have some important implications for the successful isolation, propagation, and characterization of PFA-resistant strains from clinical samples containing mixed viral populations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627655      PMCID: PMC189958     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient.

Authors:  K K Knox; W R Drobyski; D R Carrigan
Journal:  Lancet       Date:  1991-05-25       Impact factor: 79.321

2.  Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs.

Authors:  V Sullivan; D M Coen
Journal:  J Infect Dis       Date:  1991-10       Impact factor: 5.226

3.  Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation.

Authors:  W R Drobyski; K K Knox; D R Carrigan; R C Ash
Journal:  Transplantation       Date:  1991-07       Impact factor: 4.939

4.  Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection.

Authors:  W L Drew; R C Miner; D F Busch; S E Follansbee; J Gullett; S G Mehalko; S M Gordon; W F Owen; T R Matthews; W C Buhles
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

5.  Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir.

Authors:  S C Stanat; J E Reardon; A Erice; M C Jordan; W L Drew; K K Biron
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

6.  Characterization of the DNA polymerase gene of human herpesvirus 6.

Authors:  I A Teo; B E Griffin; M D Jones
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

7.  A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors.

Authors:  W A Tatarowicz; N S Lurain; K D Thompson
Journal:  J Infect Dis       Date:  1992-10       Impact factor: 5.226

8.  Development and clinical significance of a diagnostic assay based on the polymerase chain reaction for detection of human cytomegalovirus DNA in blood samples from immunocompromised patients.

Authors:  D Zipeto; M G Revello; E Silini; M Parea; E Percivalle; M Zavattoni; G Milanesi; G Gerna
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

9.  A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells.

Authors:  V Sullivan; C L Talarico; S C Stanat; M Davis; D M Coen; K K Biron
Journal:  Nature       Date:  1992-07-09       Impact factor: 49.962

10.  Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir.

Authors:  E Littler; A D Stuart; M S Chee
Journal:  Nature       Date:  1992-07-09       Impact factor: 49.962

View more
  42 in total

1.  Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories.

Authors:  S Chou; N S Lurain; A Weinberg; G Y Cai; P L Sharma; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

2.  Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I.

Authors:  Anne-Marie Fillet; Laetitia Auray; Sophie Alain; Karine Gourlain; Berthe Marie Imbert; Fatiha Najioullah; Gael Champier; Stéphanie Gouarin; Jocelyne Carquin; Nadhira Houhou; Isabelle Garrigue; Alexandra Ducancelle; Danielle Thouvenot; Marie-Christine Mazeron
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 3.  Human cytomegalovirus resistance to antiviral drugs.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Ganciclovir-resistant human herpesvirus-6 encephalitis in a liver transplant patient: a case report.

Authors:  Kelly Baldwin
Journal:  J Neurovirol       Date:  2011-02-02       Impact factor: 2.643

5.  Differentiation between polymorphisms and resistance-associated mutations in human cytomegalovirus DNA polymerase.

Authors:  Meike Chevillotte; Ina Ersing; Thomas Mertens; Jens von Einem
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

6.  Drug-resistant herpesviruses: should we look for them?

Authors:  G Boivin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

7.  Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet.

Authors:  Christian Gilbert; Arezki Azzi; Nathalie Goyette; Sheng-Xiang Lin; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

8.  Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.

Authors:  Karen K Biron; Robert J Harvey; Stanley C Chamberlain; Steven S Good; Albert A Smith; Michelle G Davis; Christine L Talarico; Wayne H Miller; Robert Ferris; Ronna E Dornsife; Sylvia C Stanat; John C Drach; Leroy B Townsend; George W Koszalka
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms.

Authors:  David L Evers; Gloria Komazin; Roger G Ptak; Dongjin Shin; Brian T Emmer; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.

Authors:  T Cihlar; M D Fuller; J M Cherrington
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.